Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - OtherRetained EarningsShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Telix Pharmaceuticals (TLX) Work In Process (2023 - 2024)

Telix Pharmaceuticals has reported Work In Process over the past 2 years, most recently at $9.1 million for Q4 2024.

  • Quarterly Work In Process rose 133.94% to $9.1 million in Q4 2024 from the year-ago period, while the trailing twelve-month figure was $9.1 million through Dec 2024, up 133.94% year-over-year, with the annual reading at $9.1 million for FY2024, 133.94% up from the prior year.
  • Work In Process was $9.1 million for Q4 2024 at Telix Pharmaceuticals, up from $3.9 million in the prior quarter.
  • Over five years, Work In Process peaked at $9.1 million in Q4 2024 and troughed at $3.9 million in Q4 2023.